Kiadis Pharma has a number of novel products in clinical development and a portfolio of preclinical programs all derived from the companies product and technology platforms.

The current status of the lead in clinical development:

• ATIR™ : ongoing phase I/II study for mismatched bone marrow transplantations, recruitment ongoing.
• Reviroc™: Phase II study completed and phase III studied anticipated to enroll early 2008
• Rhitol™:  Phase I/II study is closed for enrollment.  phase III study anticipated to enroll mid 2008